PCVX
Vaxcyte, Inc.
Biotechnology · Healthcare · United States
62.03
close · 2026-10-30
value
90
cheaper than peers90
quality
76
stronger fundamentals76
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 3 years ago | -1.8% | 86 |
| earnings yield, 3 years ago | -5.5% | 86 |
| earnings yield, 2 years ago | -6.7% | 81 |
| earnings yield, 1 year ago | -6.1% | 80 |
| earnings yield, latest year | -9.1% | 75 |
| cash flow yield, 2 years ago | -3.7% | 75 |
| cash flow yield, 1 year ago | -5.9% | 73 |
| cash flow yield, latest year | -7.3% | 69 |
| price to book | 3.26× | 42 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -30.6% | 86 |
| debt to equity | 3.9% | 54 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $10B |
| free cash flow | -$439.8M |
| employees | 507 |
| first trade | 2020-06-12 |
| next earnings | not reported |
| fundamentals updated | 2026-07-31 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -5.63 | -3.80 | -4.14 | -3.44 |
| free cash flow | -$712.5M | -$571.8M | -$364.7M | -$176.4M |
| net income | -$766.6M | -$463.9M | -$402.3M | -$223.5M |
| revenue | $0 | $0 | $0 | $0 |
| unusual items | $0 | $0 | -$75.0M | -$23.0M |